http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9062123-B2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0f72dcf498cd271135797f8d992ee588 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_26f55b2ff8141b9add7205003582d71b http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_79c0c00b07d97029439b126de6920065 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-575 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K51-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K51-088 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K49-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61M36-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K51-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K51-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-435 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-575 |
| filingDate | 2011-07-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2015-06-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9f84925e7044d3e130a515909a8133f5 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8c68e82630456ffd6c3a2f4e53134f89 |
| publicationDate | 2015-06-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-9062123-B2 |
| titleOfInvention | Labelled adrenomedullin derivatives and their use for imaging and therapy |
| abstract | The present invention relates to an adrenomedullin derivative including an adrenomedullin peptide, or a fragment thereof chelated or otherwise bound to at least one active agent. Examples of active agents include a paramagnetic element, a radioactive element and a fibrinolytic agent, among others. Paramagnetic agents have a distribution that is relatively easily shown through Magnetic Resonance Imaging (MRI). Radioactive agents have applications in imaging and delivery of radiations, depending on the specific element included in the active agent. Delivery of fibrinolytic agents mainly to a specific organ, such as for example to the lungs, allows to substantially improve the specificity and efficacy of thrombolytic therapy by allowing local delivery of the fibrinolytic agent, thereby reducing the risks of major bleeding in the therapy of the organ. If the organ is the lungs, a non-limiting example of pathology treatable with the fibrinolytic agent is pulmonary embolus. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2015246145-A1 |
| priorityDate | 2004-05-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 204.